Docente: Ludovica Putignano Voce: Brenda Barrett Da unidea di Barbara Manconi a.s. 2008/2009.
L'esofago di Barrett - Gastrolearning®
-
Upload
gastrolearning -
Category
Education
-
view
381 -
download
2
description
Transcript of L'esofago di Barrett - Gastrolearning®
![Page 1: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/1.jpg)
Barrett’s Esophagus
Alessandro RepiciDigestive Endoscopy Unit
IRCCS Istituto Clinico HumanitasMilano
![Page 2: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/2.jpg)
goblets = Barrett‘s
no goblets = no Barrett‘s
Spechler SJ 2000
Definition of Barrett
![Page 3: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/3.jpg)
Barrett‘s Definition
USA: specialized intestinal Metaplasia
UK/Japan: all columnar metaplasia
Europe: specialized intestinal Metaplasia
![Page 4: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/4.jpg)
![Page 5: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/5.jpg)
![Page 6: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/6.jpg)
![Page 7: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/7.jpg)
481 000 new cases (3.8% of the total) oesophageal cancer estimated in 2008
The sixth most common cause of death from cancer with 406 000 deaths (5.4% of the total).
More than 75% of the cases in developing countries are squamous
More than 60% of the cases in western countries are adenoca
280 000 new cases of LGD and HGD BE are expected in 2012
![Page 8: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/8.jpg)
Incidence of BE is increasing in men under 60 years
BE/1000 scop
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
1996 1997 1998 1999 2000 2001 2002 2003
Man <60
Man >60
Vrouw <60
Vrouw >60
van Soest et al. Gut 2005
![Page 9: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/9.jpg)
EAC : lethal, rapidly rising incidence
J Natl Cancer Inst, June 2005
Relative incidence of Esophageal AdenoCa/other malignancies
Disease specific incidence rates/ mortality of Esophageal AdenoCa
![Page 10: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/10.jpg)
Risk of progression may be lower than previously thought
EAC incidence in NDBE
3.3 per 1000 patient years
Desai Gut 2012
![Page 11: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/11.jpg)
Mortality in BE
Sikkema Clin Gastro Hepatology 2010
![Page 12: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/12.jpg)
Key Features for the Endoscopic Recognition of Barrett’s Esophagus
Locate gastro-oesophageal junction
Recognise the squamocolumnar junction
Describe extent consistently
![Page 13: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/13.jpg)
Endoscopic recognition of the columnar lined esophagus
![Page 14: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/14.jpg)
Endoscopic BE: Prague C&M Criteria
• Based on – Circumference and Maximum extent
• Patient with 5 cm long Barrett’s, distal 2 cm circumferential and proximal 3 cm in form of a tongue
Barrett’s: C2M5
C2
M5
Sharma P et al, Gastroenterology 2006
![Page 15: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/15.jpg)
• Endoscopic surveillance using white-light endoscopy (WLE)
• Random 4-quadrant biopsies of every 1 to 2 cm of the BE segment (Seattle protocol)
• Targeted biopsies of any endoscopically visible
lesions
Bennett C, Vakil N, Bergman J, et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal
adenocarcinoma, based on a Delphi process. Gastroenterology 2012;143:336–46
![Page 16: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/16.jpg)
X
X
X
X
X
XX
X
X
X
X X
Seattle Protocol
2cm
2cm
Disadvantages:
-Time consuming
-Risk of bleeding
-Poor adherence
-Costs for the health care
BSG guidelines 2005; Wang KK, AmJG 2008; Spechler SJ, Gastro 2011Curvers WL, Eur J Gastro Hep 2008; Abrams JA, Clin Gastro Hep 2009, Wani S, Gastroenterology 2011
![Page 17: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/17.jpg)
Praga & Seattle protocol
• Praga classification adopted in less 40%
• Seattle protocol adherence <50%
• Correct sampling and collection of specimens 35%
• High Res/Def scope used randomly
• Only those centers with research interest in BE showed excellent compliance
Sharma P, DDW 2012
![Page 18: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/18.jpg)
Barrett’s Inspection Time (BIT)
Longer BIT led to more HGD/EAC detection (p=0.001) despite no difference in BE length (p=0.10)
Gupta N et al. GIE 2012
![Page 19: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/19.jpg)
What look for and how
• Mucosal irregularities/nodulesMucosal irregularities/nodules– Acetic acid
– Methylene blue
– Electronic chromoendoscopy
• Pit patternPit pattern– Methylene blue and electronic chromo
• Vascular patternVascular pattern– Electronic chromoendoscopy
![Page 20: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/20.jpg)
- Sedation
- Esophagus should be carefully cleaned
- Scope gradually withdrawn in inflated fashion
- Esophagus should gradually be deflated to reveal any
irregularities maybe stretched out during inflation
- Special attention at area between 12 and 6 o’clock
- Inspect in retroflexed position when hiatal hernia
Careful and dedicated technique
Curvers WL; Endoscopy 2008Sharma P; IMAGE 2012
“look longer, biopsy less”
“look 2 minutes x cm of Barrett” !!!
![Page 21: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/21.jpg)
Retroversion
![Page 22: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/22.jpg)
Examination in inflation & deflation
![Page 23: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/23.jpg)
Where is the dysplasia?
Pech et.al. Endoscopy 2007;39:588-593Kariawasan et.al. GIE 2012;75:938-44
![Page 24: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/24.jpg)
New endoscopic modalities to detect early cancer in BE
CHROMOENDOSCOPYAUTOFLUORESENCE
ENDOSCOPYCONFOCAL
ENDOMICROSCOPY
OPTICAL COHERENCE TOMOGRAPHY
HIGH RESOLUTION MICRO ENDOSCOPY
ENDOCYTOOSCOPY
![Page 25: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/25.jpg)
Acetic Acid• Fortun: APT 2005-15% pts had histologic
upgrade with acetic acid
• Pohl: Endoscopy 2007—sensitivity 87% PV 39%
• Curvers: Gastro 2008—no increased yield of AA over HRE
• Longcroft-Wheaton: CGH 2010-specificity 80% sensitivity : 95%
• Pohl: AJG 2010: Sensitivity 97% specificity 66%
![Page 26: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/26.jpg)
Disadvantages of Chromoendoscopy
• Operator-dependant
• Labor-intensive
• Requires the use of dyes
• Spraying catheters
• Unequal distribution of dye
![Page 27: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/27.jpg)
![Page 28: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/28.jpg)
The pathway to BE cancer
Low Grade Dysplasia
High Grade Dysplasia
Intramucosal cancer
→ Architectural changes
→ Architectural changes Cellular changes
→ Architectural changes Cellular changes Macroscopic changes
![Page 29: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/29.jpg)
How dangerous is LGD?
• Low grade dysplasia has 3 - 6% 5yr cancer risk
• Grading dysplasia is difficult for pathologists
• Is low-grade always low-grade?
• Amsterdam Gut Club Barrett registry
– More than 3000 pts in 16 hospitals
– 110 LGD cases diagnosed between ’00-’06
![Page 30: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/30.jpg)
110 LGD pts reviewed 110 LGD pts reviewed
by 2 expert pathologistsby 2 expert pathologists
87 pts NDBE87 pts NDBE
(80%)(80%)
13 pts Indef13 pts Indef
(12%)(12%)
10 pts LGD10 pts LGD
(8%)(8%)
60% HGD/Ca60% HGD/Ca60% HGD/Ca60% HGD/CaNo HGD/Ca No HGD/Ca No HGD/Ca No HGD/Ca
Median FU of 42 monthsMedian FU of 42 monthsMedian FU of 42 monthsMedian FU of 42 months
Pouw et al, GIE 2010
![Page 31: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/31.jpg)
How dangerous is “real” LGD?
![Page 32: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/32.jpg)
Treatment is related to different factors
• Grade/Stage of BE neoplasia• Endoscopic morphology (flat vs nodular lesion)
• Extension of the neoplasia (multifocal vs single dysplatic area)
• Site of the BE• Extension of the BE• Previous treatments
![Page 33: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/33.jpg)
Ideal treatment for LGD (& NDBE)
• Safe (<1% SAE’s for LGD, <0,1 for NDBE)
• Effective (reducing cancer risk)
• Minimally invasive
• Obviating need for future surveillance
• Not more expensive than ??? yrs of surveillance
• EMR? MBM? PDT? RFA? Cryo?
![Page 34: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/34.jpg)
Radiofrequency energy ablation – HALO360 system
magnified electrode
Controlled ablation depth by:Controlled ablation depth by:• Bipolar balloon based electrodeBipolar balloon based electrode
• Fixed energy densityFixed energy density
• Fixed powerFixed power
• Automated RF deliveryAutomated RF delivery
![Page 35: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/35.jpg)
Human Esophagus
Muscularis Mucosae
Submucosa
Muscularis Propria
GG
Surgical Depth
PDT, APC & Cryo Depth?
Lamina PropriaEpithelium
Keys to Endotherapy:1.Uniform mucosal removal2.Controlled depth of ablation
RFA Depth
EMR/ESD Depth
![Page 36: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/36.jpg)
Focal ablation – HALO90 system
![Page 37: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/37.jpg)
A Randomized, Multicenter, Sham Controlled Trial of RF Ablation
• 128 patients with BE and dysplasia (LGD/HGD)• Mean BE length 5 cm; 12 month follow up
IM Eradication (n=127)
LGD Eradication (n=64)
HGD Eradication (n=63)
2%
23% 19%
77%*
90%* 81%
*
Patients%
0
10
20
30
40
50
60
70
80
90
100
SHAM
RFA
p<0.001
Shaheen N et al. NEJM 2009
![Page 38: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/38.jpg)
![Page 39: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/39.jpg)
How effective is RFA?
• RFA extensively studied for HGD and early ca
• Often combination of mucosectomy with RFA
• RFA has excellent results in expert hands
• RFA is only a small part of patient care– High quality endoscopy (team + equipment)
– Expert pathology
– Counselling
– .........
![Page 40: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/40.jpg)
DEFINITION OF HGD AND EARLY CANCER DEFINITION OF HGD AND EARLY CANCER ON BARRETT’S ESOPHAGUSON BARRETT’S ESOPHAGUS
High-grade dysplasia exhibits more severe cytologic atypia and greater architecturalcomplexity than does low-grade, but the cutoff between low-grade and high-grade dysplasia is difficult to define.
In high grade dysplasia the neoplastic glands are irregularly shaped and are morecrowded, separated only by thin strands of fibrovascular tissue.
![Page 41: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/41.jpg)
A 42y old male with IM Ca on BE
![Page 42: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/42.jpg)
How much frequent is HGD on flat Barrett?
• 150 cases of nodular lesions or focal abnormalities
• 143 flat mucosa
• Flat lesions were associated with a reduced risk of HGD or invasive cancer
![Page 43: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/43.jpg)
![Page 44: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/44.jpg)
Incidence of lymph node metastasesIncidence of lymph node metastases
Level of infiltrationLevel of infiltration Lymph node (N)Lymph node (N)
IM esophagusIM esophagus (Adenoca)(Adenoca) 0.3-0.5%0.3-0.5%
IM esophagus (SCC)IM esophagus (SCC) 8%8%Sm1 (Adenoca)Sm1 (Adenoca) 2%2%
Sm1 (SCC)Sm1 (SCC) 10-14%10-14%
Endoscopic management of BE: rationaleEndoscopic management of BE: rationale
![Page 45: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/45.jpg)
T1 m1-sm1 Esophageal Adenocarcinoma: a very low risk of lymphatic dissemination
Westerterp M, Virchows Arch, 2005
*
* Diameter of Node+: 12 mm
![Page 46: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/46.jpg)
Prevalence of T1b carcinoma at esophagectomy for HGD-IMC
• Retrospective study, 60 pts. with HGD or IMC at biopsy.
• Pts. with endoscopic evidence of mass and with EUS evidence of sm invasion were excluded
Wang V.S., Gastrointestinal Endoscopy, 2009
![Page 47: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/47.jpg)
Muscolaris mucosae
The Paris Endoscopic Classification of Superficial Neoplastic Lesions
Gastrointest Endosc 2003
Cut-off limit
500 µ
m
sm
mp
Barrett’s Esophagus
ENDOSCOPY SURGERY
sm1sm1
![Page 48: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/48.jpg)
AGA Medical Position Statement
Recommend endoscopic therapy rather than surveillance for confirmed HGD
Recommend EMR in patients withvisible lesions
Strong recommendation
Strong recommendation
Gastroenterology March 2011
![Page 49: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/49.jpg)
The pathway to BE cancer
Low Grade Dysplasia
High Grade Dysplasia
Intramucosal cancer
→ Surveillance or Radiofrequency
→ EMR or Radiofrequency or Combination of ER and RF
→ EMR or ESD or Radiofrequency or Combination of ER and RF or Surgery
![Page 50: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/50.jpg)
Endoscopic approach for early EC is the most effective and less expensive option:
a decision analysis model
The position of the threshold is determined by 5-year survival rate after endoscpic therapy among N+ pts: 10%, 20%, 25%
Pohl H., Gastrointestinal Endoscopy , 2009
![Page 51: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/51.jpg)
Staging of early neoplastic lesionsStaging of early neoplastic lesions
• Mucosal/submucosal Mucosal/submucosal
• Isolated lesion/multifocal lesionsIsolated lesion/multifocal lesions
• Nodes involvementNodes involvement
• Distant metastasisDistant metastasis
![Page 52: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/52.jpg)
Staging dysplasia/early neoplasiadysplasia/early neoplasia in BE
• HD/HR Endoscopy
• Chromoendoscopy and Electronic Chromoendoscopy
• Radial EUS
• HF miniprobes EUS
• Linear EUS with FNA for nodes
Mucosal Resection may be considered a strategic staging modality
![Page 53: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/53.jpg)
EC staging by EUS in 266 pts. who had esophagectomy without induction-CT
• EUS erroneously classified T3-T4 in 42 pts (16%)
• EUS is insesitive for N+, but with high specificity
• EUS is completely insensitive for M+
Gregory Zuccaro, Am J Gastroenterol, 2005
![Page 54: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/54.jpg)
Accuracy of EUS in early EC
Proportion of correct results
EUSAccuracy
Mucosal Invasion
Sub-Mucosal Invasion
Chemaly, Endoscopy 2008 62 13 75/102 73.5 %
May , Gut 2004 62 12 74/93 79.6%
Larghi, GIE 2005 9 NA 9/15 60.0%
![Page 55: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/55.jpg)
EUS performance in EC: overstaging and understaging
Pech O, Endoscopy, 2010
![Page 56: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/56.jpg)
Reasons for poor EUS performance
• Microscopic definition of disease
• Hiatal ernia
• No water assistance
• Duplication of muscolaris mucosae
![Page 57: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/57.jpg)
![Page 58: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/58.jpg)
Endoscopic Resection (ER)
• ER allows for histological correlation, enabling optimal selection of patients for endoscopic treatment.
• However, after focal ER for early Barrett neoplasia, metachronous lesions are observed in 30% during follow-up.
![Page 59: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/59.jpg)
Endoscopic Resection Techniques
• Standard snare resection
• Cap assisted resection
• Band-ligator assisted
• Submucosal dissection
![Page 60: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/60.jpg)
CAP-ASSISTED
WITH BAND-LIGATOR
![Page 61: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/61.jpg)
ER-cap techniqueER-cap technique
![Page 62: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/62.jpg)
Multi-Band Mucosectomy (DuetteR)
![Page 63: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/63.jpg)
How to chose the right approach
• Location
• Extension of the targeted area
• Presence of visible nodules
![Page 64: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/64.jpg)
4 bleeding10033539Conio
None75472318Mino-Kenudson
Not reported100452340Larghi
1 bleeding993550115Peck
2 stenosis100243428May
1 bleeding100131317Buttar
None100171525Nijhawan
1 bleeding97141235Ell
ComplicationsCompleteb Response
Recurrencea
%
F-up (mo)
# Patients
Authors
aMetachronous/recurrent lesionsbEnd of f-up after multimodality (EMR-APC-PDT) treatment
Larghi et al., Gastrointest Endosc Clin N Am 2007
EMR for HGD or IMC (visible lesions)
![Page 65: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/65.jpg)
Randomized, controlled trial in tertiary-care and community-care centers.
Piecemeal ER was performed by using ER-cap (n 42) or MBM (n 42).
Outcome Measurements: Safety, efficacy, procedure time, costs.
Results: Procedure time (34 vs 50 minutes; P .02) and costs (€240 vs €322; P .01) were significantly less with MBM compared with ER-cap. MBM resulted in smaller resection specimens than ER-cap (18 13 mm vs 20 15 mm; P .01).
Maximum thicknesses of specimens and resected submucosa were not significantly different.
There were no clinically relevant bleeding episodes. Four perforations occurred, 3 with ER-cap, 1 with MBM
Rouw PE, GIE 2011
![Page 66: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/66.jpg)
In this intense, structured training program, the first 120 esophageal endoscopic resections performed by six participants were associated with a 5.0% perforation rate5.0% perforation rate.
Although perforations were adequately managed, performing performing 20 endoscopic resections may not be 20 endoscopic resections may not be sufficient to reach sufficient to reach the peak of the learning curve in endoscopic resection
Van Vilsterein FGI, et al Endoscopy 2012
![Page 67: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/67.jpg)
EMR of early cancer and high-grade dysplasia at distal esophagus and GEJ
• 1120 ERs in 6 years (680 pts)
• Mortality 0
• Major complications 1.1% (13 patients)
Perforation 1
Bleeding 10 (epinephrine, clip)
Stenosis 8 (bougienage)
• 5-yr survival rate 79%
Ell C, UEGW 2010
![Page 68: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/68.jpg)
• “Low-risk”: sm1, type I/II, no vascular or lymphatic involvement, well or moderately differentiated
• 21 patients: 19 treated by endoscopy
• Complete remission obtained in 95% (18/19) over 5.3 months
• ER is associated with favorable outcomes even in case of “low-risk” submucosal Barrett Cancer.
Manner H et al AJG 2008
![Page 69: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/69.jpg)
Combine endoscopic resection & Combine endoscopic resection & ablationablation
![Page 70: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/70.jpg)
The buried BE glands beneath squamous The buried BE glands beneath squamous epitheliumepithelium
A total of 47 patients’ initial mucosectomy slides were reviewed
Buried BE underneath the squamous resection margin was identified in 13/47 patients (28%)
The linear distance of the Barrett’s epithelium from the resection’s squamous margin ranged from 0.8 to 5.6 mm (mean 2.3 mm and median 1.9 mm).
Histopathology revealed nondysplastic buried BE in 3 patients, HGD in 9 patients, and IMC in 1 patient.
Chenneat J et al GIE 2010
![Page 71: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/71.jpg)
Endotherapy vs SurgeryThis Cochrane review has indicated that there are
no randomised control trials to compare managementoptions in this vital area, therefore trials should be
undertaken as a matter of urgency
The problems with such randomised methods are:1)Standardising surgery and endotherapy
2)Standardising histopathology3)Assessing which patients are fit or unfit for surgery
4)At least 5 years survival
Cochrane Database Syst Rev Apr 2009
![Page 72: L'esofago di Barrett - Gastrolearning®](https://reader035.fdocuments.in/reader035/viewer/2022062405/556b8ebdd8b42ada358b4647/html5/thumbnails/72.jpg)
Prasad A et al Gastroenterology 2009
Retrospective analysis of 178 patients treated by Endoscopy (132) or Surgery 46